Whitehawk Therapeutics appointed Dr. Vijay Iyengar to its board, effective Sept. 9, bringing over 20 years of oncology and corporate strategy experience. This addition bolsters the company's leadership as it advances its ADC pipeline and aims to commercialize treatments.